Table 1.
The results of characteristics of patients by univariate analysis.
| IRP (n = 48) | Non-IRP (N = 142) | P-value | |
|---|---|---|---|
| Sex | 0.331 | ||
| Male | 41 (85.4) | 110 (77.5) | |
| Female | 7 (14.6) | 32 (22.5) | |
| Age (y) | 61.00 [54.75, 67.00] | 58.00 [52.00, 67.00] | 0.358 |
| BMI | 22.98 [20.82, 25.38] | 23.56 [21.48, 25.08] | 0.592 |
| Body Temperature (°C) | 36.60 [36.50, 36.80] | 36.50 [36.30, 36.70] | 0.045 |
| Systolic blood pressure | 121.50 [108.25, 129.00] | 124.00 [112.25, 133.75] | 0.346 |
| Diastolic blood pressure | 77.00 [70.00, 83.75] | 79.50 [71.00, 85.00] | 0.442 |
| Smoking (yes) | 31 (64.6) | 72 (50.7) | 0.133 |
| Drinking (yes) | 13 (27.1) | 27 (19.0) | 0.327 |
| KPS score | 0.169 | ||
| ≤70 | 17 (35.4) | 31 (21.8) | |
| 80 | 88 (62.0) | 24 (50.0) | |
| ≥90 | 7 (14.6) | 23 (16.2) | |
| Cancer stage | 0.708 | ||
| I | 0 (0.0) | 1 (0.7) | |
| II | 1 (2.1) | 3 (2.1) | |
| III | 18 (37.5) | 42 (29.8) | |
| IV | 29 (60.4) | 95 (67.4) | |
| Cancer category | 0.013 | ||
| NSCLC | 42 (87.5) | 96 (67.6) | |
| Non NSCLC1 | 6 | 46 | |
| Type of underlying diseases | |||
| Hypertension | 11 (22.9) | 20 (14.1) | 0.228 |
| Diabetes | 10 (20.8) | 16 (11.3) | 0.154 |
| Coronary Heart Disease | 4 (8.3) | 7 (4.9) | 0.474 |
| Viral Hepatitis | 3 (6.2) | 13 (9.2) | 0.765 |
| Lung-related disease | 8 (16.7) | 18 (12.7) | 0.651 |
| Number of underlying diseases | <0.001 | ||
| 0 | 6 (12.5) | 62 (43.7) | |
| 1 | 15 (31.2) | 52 (36.6) | |
| ≥2 | 27 (56.2) | 28 (19.7) | |
| History of lung diseases | 2 (4.2) | 35 (32.7) | 0.004 |
| ICI drugs | 0.047 | ||
| PD-L1 | 5 (10.4) | 4 (2.8) | |
| PD-1 | 43 (89.6) | 138 (97.2) | |
| ICIs drugs | <0.001 | ||
| Attilizumab | 2 (4.2) | 3 (2.1) | |
| Carrilizumab | 19 (39.6) | 36 (25.4) | |
| Tirelizumab | 3 (6.2) | 31 (21.8) | |
| Nevirumab | 2 (4.2) | 6 (4.2) | |
| Perbolizumab | 11 (22.9) | 12 (8.5) | |
| Toripalimab | 5 (10.4) | 18 (12.7) | |
| Sindillizumab | 0 (0.0) | 33 (23.2) | |
| others | 6 (12.5) | 2 (1.4) | |
| ICIs drug dosage (mg) | 200.00 [200.00, 200.00] |
200.00 [200.00, 200.00] |
0.158 |
| First time for immunotherapy (yes) | 45 (93.8) | 129 (90.8) | 0.765 |
| Course of cancer treatment | 4.00 [3.00, 7.00] | 5.00 [3.00, 7.00] | 0.222 |
| Number of other antitumor drugs | 0.153 | ||
| 0 | 8 (17.0) | 35 (24.6) | |
| 1 | 14 (29.8) | 21 (14.8) | |
| 2 | 24 (51.1) | 83 (58.5) | |
| 3 | 1 (2.1) | 2 (1.4) | |
| ≥4 | 0 (0.0) | 1 (0.7) | |
| History of other antitumor drugs exposure (yes) | 39 (83.0) | 107 (75.4) | 0.546 |
| Number of non-antitumor drugs | 0.027 | ||
| 0 | 13 (50.0) | 102 (74.5) | |
| 1 | 3 (11.5) | 17 (12.4) | |
| 2 | 4 (15.4) | 7 (5.1) | |
| 3 | 3 (11.5) | 5 (3.6) | |
| 4 | 2 (7.7) | 3 (2.2) | |
| 5 | 1 (3.8) | 1 (0.7) | |
| ≥6 | 0 (0.0) | 2 (1.5) | |
| History of non-antitumor drugs exposure (yes) | 13 (50) | 35 (25.5) | 0.005 |
| Surgery (yes) | 11 (26.2) | 42 (29.6) | 0.817 |
| History of radiation therapy (yes) | 27 (64.3) | 48 (33.8) | 0.002 |
| History of chemotherapy (yes) | 32 (66.7) | 78 (54.9) | 0.210 |
| Number of previous anti-tumor drugs | 0.070 | ||
| 0 | 17 (35.4) | 53 (40.2) | |
| 1 | 1 (2.1) | 3 (2.3) | |
| 2 | 28 (58.3) | 51 (38.6) | |
| 3 | 2 (4.2) | 23 (17.4) | |
| 4 | 0 (0.0) | 1 (0.8) | |
| ≥5 | 0 (0.0) | 1 (0.8) | |
| History of anti-tumor drugs exposure (yes) | 31 (64.6) | 89 (62.7) | 0.866 |
| CD4+ lymphocyte count | 264.50 [186.75, 490.00] |
403.50 [256.25, 582.75] |
0.054 |
| Percentage of CD4+ lymphocytes | 31.05 [25.62, 41.05] |
35.20 [28.33, 44.88] |
0.102 |
| CD8+ lymphocyte count | 260.50 [189.50, 356.75] |
308.00 [183.75, 406.50] |
0.249 |
| Percentage of CD8+ lymphocytes | 28.20 [21.52, 37.38] |
26.75 [20.52, 33.22] | 0.565 |
| T lymphocyte count | 570.00 [427.50, 867.25] |
752.00 [554.50, 1049.50] |
0.049 |
| Percentage of T lymphocytes | 67.60 [58.80, 75.55] | 71.10 [62.00, 77.35] | 0.292 |
| B lymphocyte count | 77.50 [31.75, 129.75] | 90.00 [53.50, 141.50] | 0.331 |
| Percentage of B lymphocytes | 7.90 [4.65, 13.22] | 8.50 [5.35, 12.85] | 0.629 |
| NK cell count | 201.50 [124.00, 297.25] | 206.00 [122.00, 289.50] | 0.896 |
| Percentage of NK cell | 18.95 [14.78, 31.52] | 18.60 [12.45, 27.85] | 0.488 |
| Red blood cell | 3.92 [3.38, 4.34] | 3.84 [3.40, 4.17] | 0.592 |
| Hemoglobin | 118.50 [103.75, 127.00] | 116.50 [106.75, 129.00] | 0.781 |
| Hemameba | 5.72 [4.30, 7.91] | 5.17 [4.15, 6.56] | 0.139 |
| Percentage of lymphocytes | 17.75 [11.18, 24.52] | 20.25 [13.30, 27.77] | 0.151 |
| Percentage of monpcytes | 9.20 [6.00, 12.35] | 10.05 [7.60, 12.50] | 0.370 |
| Percentage of neutrophilic granulocyte | 68.70 [59.65, 79.20] | 66.40 [58.43, 74.35] | 0.278 |
| Percentage of eosinophils | 1.00 [0.30, 3.80] | 1.90 [0.60, 3.15] | 0.379 |
| Percentage of basophils | 0.30 [0.10, 0.60] | 0.40 [0.30, 0.70] | 0.034 |
| Blood platelet | 184.00 [144.25, 256.50] | 181.00 [139.50, 233.75] | 0.354 |
1: non-NSCLC contains malignant melanoma, small cell lung cancer, nasopharyngeal carcinoma, cervical cancer, Hodgkin’s lymphoma, ovarian cancer, diffuse large B-cell lymphoma, esophageal carcinoma, gastric cancer, bladder cancer and others. The bold values means less than 0.05.